山东百龙创园生物科技股份有限公司 证券代码：605016 证券简称：百龙创园 公告编号：2025-070 关于召开 2025 年第三季度业绩暨现金分红说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 11 月 10 日 （星期一） 09:30-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 11 月 03 日 （星期一） 至 11 月 07 日 （星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 blcyzqb@sdblcy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 山东百龙创园生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Company Overview - Shandong Bailong Chuangyuan was established on December 30, 2005, and went public on April 21, 2021. The company specializes in the research, production, and sales of prebiotic products, dietary fiber products, and health sweeteners [8]. - The company's revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - It has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4]. Stock Performance - As of October 29, the stock price increased by 1.07%, with a trading volume of 57.83 million yuan and a market capitalization of 8.325 billion yuan [1]. - The average trading cost of the stock is 20.46 yuan, with the current price approaching a resistance level of 19.90 yuan, indicating potential for upward movement if the resistance is broken [7]. Shareholder Composition - As of June 30, 2025, notable shareholders include Penghua New Emerging Industry Mixed Fund and Hong Kong Central Clearing Limited, with some new shareholders entering the top ten list [10].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and healthy sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Strategic Investments and Market Position - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial benefits [3] - The company’s overseas revenue accounts for 60.62% of total revenue, benefiting from the depreciation of the RMB [4] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] Group 4: Market Activity - On October 28, the company's stock price fell by 1.06%, with a trading volume of 55.7288 million yuan and a turnover rate of 0.68%, resulting in a total market capitalization of 8.236 billion yuan [1] - The stock has shown no significant trend in net inflow from major investors, with a net outflow of 1.7108 million yuan today [5][6]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank amid the depreciation of the RMB. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8] - As of August 29, the company had 12,700 shareholders, a decrease of 0.43%, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3] - The company is recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance and Trading Activity - On October 23, the company's stock rose by 0.47%, with a trading volume of 46.47 million yuan and a turnover rate of 0.58%, bringing the total market capitalization to 8.08 billion yuan [1] - The average trading cost of the stock is 20.48 yuan, with recent buying activity noted, although the strength of this buying is not strong [7]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank amid the depreciation of the RMB. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other sources [8] - As of August 29, the number of shareholders is 12,700, a decrease of 0.43%, while the average circulating shares per person increased by 0.43% to 33,056 shares [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance - On October 21, the company's stock rose by 1.91%, with a trading volume of 62.88 million yuan and a turnover rate of 0.78%, leading to a total market capitalization of 8.08 billion yuan [1] - The average trading cost of the stock is 20.50 yuan, with a current support level at 19.05 yuan [7]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price but has strong fundamentals, including a focus on health-oriented sweeteners and recognition as a "specialized and innovative" enterprise [1][2][4]. Company Overview - Shandong Bailong Chuangyuan was established on December 30, 2005, and went public on April 21, 2021. The company specializes in the research, production, and sales of prebiotic products, dietary fiber products, starch sugar (alcohol) products, and health sweeteners [8]. - The company's revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%. The net profit attributable to shareholders was 170 million yuan, with a year-on-year increase of 42.00% [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Shareholding and Market Position - As of June 30, 2025, the top ten circulating shareholders include various funds, with notable increases in holdings from several new institutional investors [10]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial stability [3]. Industry Context - The company is positioned within the sugar substitute market, specifically focusing on allulose, a rare sugar that offers a similar taste to sucrose but with significantly lower calories, making it ideal for obesity and diabetes management [2]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the Chinese yuan [4]. Technical Analysis - The average trading cost of the stock is 20.50 yuan, with recent trading showing a decrease in holdings but at a slowing rate. The current stock price is near a support level of 18.76 yuan, indicating potential for rebound or further decline if this level is breached [7].

Core Insights - Bailong Chuangyuan achieved a net profit attributable to shareholders of 265 million yuan in the first three quarters of 2025, representing a year-on-year increase of 44.93% [1] - In Q3 2025, the company reported a net profit of 94.85 million yuan, marking a year-on-year growth of 50.48% and a quarter-on-quarter increase of 7.34% [1] Revenue and Profitability - The company's revenue and gross margin have both increased due to capacity expansion and a decline in raw material prices [1] - The implementation of domestic allulose policies has allowed Bailong Chuangyuan to leverage its technological, cost, and capacity advantages to capture new market opportunities [1] Strategic Developments - The optimization of the cost structure at the Thailand factory enhances the company's competitiveness in the European, American, and Southeast Asian markets [1] - Upon project completion, the company will establish a dual capacity hub in Shandong and Thailand, further solidifying its market share in the global health food raw materials sector through cost optimization and a regional supply network [1] Investment Rating - The report maintains an "Overweight" rating for Bailong Chuangyuan [1]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported continuous growth in Q3 2025, with revenue reaching 969 million yuan, a year-on-year increase of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [5] - The company's third-quarter revenue was 319 million yuan, reflecting a year-on-year increase of 10.61% but a quarter-on-quarter decrease of 4.82% [5] - The growth in revenue and gross margin is attributed to capacity expansion and a decline in raw material prices, with significant contributions from the soluble dietary fiber and crystalline sugar projects launched in May 2024 [6] - The domestic market for D-alloheptulose has officially opened, allowing the company to leverage its technological and production advantages to capture new market opportunities [7] - The establishment of a production base in Thailand is expected to enhance cost efficiency and strengthen the company's competitive position in global markets [8][9] Financial Summary - The company expects net profits for 2025-2027 to be 338 million, 412 million, and 536 million yuan respectively, with corresponding P/E ratios of 25, 21, and 16 times [10] - Key financial indicators for 2025E include revenue of 1.421 billion yuan, a net profit of 338 million yuan, and a gross margin of 35.5% [11] - The company’s cash flow from operating activities is projected to be 263 million yuan in 2025E [14]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with revenue reaching 969 million yuan, up 18.10% year-on-year, and net profit attributable to shareholders at 265 million yuan, up 44.93% year-on-year [1] - The growth in profit is attributed to product structure optimization and capacity release, particularly from the new projects in soluble dietary fiber and crystallized sugar [1] - The company is expected to further enhance its revenue and profit scale with ongoing projects, including the functional sugar drying expansion and the new health food raw material factory in Thailand [1] Revenue and Profit Performance - For Q3 2025, the company achieved revenue of 320 million yuan, a year-on-year increase of 10.61%, and a net profit of 95 million yuan, up 50.48% year-on-year [1] - The overall profit growth trend remains strong, driven by the optimization of product structure [1] Market Potential and Product Development - The approval of D-allohexose as a new food raw material in July 2025 marks a new phase for its domestic development, with broad application scenarios and significant potential for demand expansion [2] - The company has been proactive in developing related products with various clients, indicating a strong pipeline for D-allohexose products [2] Profit Forecast and Investment Rating - The company is projected to achieve net profits of 357 million yuan, 474 million yuan, and 620 million yuan for 2025-2027, representing year-on-year growth rates of 45%, 33%, and 31% respectively [2] - Current stock prices correspond to price-to-earnings ratios of 25X, 19X, and 15X for 2025-2027, maintaining a "strong buy" rating [2]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing fluctuations in stock performance, with a recent drop of 4.86% and a market capitalization of 8.64 billion yuan. The company is involved in the production of health sweeteners, particularly allulose, which is beneficial for obesity and diabetes patients [1][2]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with revenue contributions of 54.15% from dietary fibers, 28.00% from prebiotics, and 13.57% from health sweeteners [8]. - As of August 29, the company had 12,700 shareholders, with an average of 33,056 circulating shares per shareholder, reflecting a slight decrease in the number of shareholders [8]. Group 2: Financial Performance - For the first half of 2025, the company reported a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Group 3: Investment Highlights - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial benefits [3]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the Chinese yuan [4]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitiveness and stability within the industry [4]. Group 4: Market Activity - The stock has seen a net inflow of 13.56 million yuan from major investors today, with a total trading volume of 349 million yuan and a turnover rate of 3.92% [1][5]. - The average trading cost of the stock is 20.52 yuan, with the current price near a support level of 20.53 yuan, indicating potential for a rebound if this level holds [7].